[12] Patent
[11] Patent No.:GC0007537  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125764
Date of the Decision to Grant the Patent:08/Apr/2018

[21] Application No.:GC 2015-29345

[22] Filing Date:4/5/2015

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
19/5/2014
62/000,253

[72] Inventors:1- Donmienne Doen Mun LEUNGŲŒ2- Jianghuai XU

[73] Owner: Eli Lilly And Company, Lilly Corporate Center, Indianapolis 46206-6288, Indiana , USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 39/395; A61P 35/00; C07K 16/22 (2006.01)

[56] Cited Documents:

-US 2011/0027286 A1 (THURSTON et al) 03 February 2011
-US 2010/0159587 A1 (BRINKMANN et al) 24 June 2010
-US2006246071 A1 (GREEN et al) 02 November 2006
 
Examiner: PH. Mohammad S. AlMousa

[54] ANG2 ANTIBODIES
[57] Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
No. of claims: 15


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.